Valeant vows to refute 'phantom sales' allegations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Nasdaq climbs to record after softer jobs data cools rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Endo Int'l (ENDP), BioDelivery Sciences (BDSI) Announce FDA Approval of BELBUCA as Chronic Pain Treatment
October 26, 2015 6:26 AM EDTEndo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI), announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. BELBUCA, which is the first and only buprenorphine developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management, is... More
Horizon Pharma (HZNP) Issues Statement to Correct 'Misinformation in the Marketplace'
October 22, 2015 5:41 PM EDTHorizon Pharma (NASDAQ: HZNP) today provided the following statement to correct misinformation in the marketplace:
Horizon takes seriously its responsibility to ensure patients have access to our medicines. Horizon enhances patients' access through several programs, one of which ensures that patients have a low out-of-pocket cost for Horizon medicines. This has... More